Targeting high-grade B cell lymphoma with CD19-specific T cells

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Adoptive T cell therapy is a crucial treatment for chemotherapy-resistant malignant diseases.
• The B cell differentiation antigen CD19 is investigated as a potential rejection antigen.

Purpose of the Study:

• To evaluate CD19 as a rejection antigen in a murine B cell lymphoma model.
• To identify protective epitopes within the CD19 molecule for therapeutic development.

Main Methods:

• Utilizing a murine high-grade B cell lymphoma model.
• Employing T cell depletion and heterotypic vaccination strategies.
• Analyzing T cell responses to CD19-derived peptides via IFNγ secretion.

Main Results:

• CD19(-/-) mice showed increased survival and protection against tumor challenge compared to WT mice.
• T cell depletion abrogated the protective immune response.
• CD19 vaccination significantly improved survival, with CD19 peptide 27 identified as a dominant epitope.
• A CD19 peptide 27-specific CD4(+) T cell line demonstrated therapeutic efficacy in both CD19(-/-) and WT mice.

Conclusions:

• CD19-specific CD4(+) T cells are highlighted as a viable strategy for adoptive T cell therapy.
• This approach holds potential for treating B cell lymphomas, including those with minimal residual disease.